| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3199186 | Journal of Allergy and Clinical Immunology | 2011 | 15 Pages |
Abstract
Mepolizumab achieved a statistically significant reduction in NP size for at least 1 month after dosing in 12 of 20 patients. IL-5 inhibition is a potential novel therapeutic approach in patients with severe eosinophilic nasal polyposis.
Keywords
CRSsNPCFBAnti–IL-5CRSwNPTPsIL-5RαNasal peak inspiratory flowLOCFECPchange from baselineAUCMPOEosinophilscomputed tomographyChronic rhinosinusitis with nasal polypsChronic rhinosinusitis without nasal polypsChronic rhinosinusitisLDLLower detection limitarea under the curveMepolizumabmyeloperoxidaseEosinophil cationic proteinNasal polypNasal polyposis
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Philippe MD, PhD, Nicholas MD, Tom PhD, Kristel PhD, Thibaut MD, PhD, Frederic MD, Natalie MSc, Katrien MSc, Ana R. PhD, Richard P. MD, PhD, Claus MD, PhD,